Table 2.
Profile of irAEs.
| Patients, n (%) | Median days to onset | Treatment interruption, n | Permanent treatment discontinuation, n | Received systemic steroid treatment, n | |||
|---|---|---|---|---|---|---|---|
| Total | Grade 1/2 | Grade 3/4 | |||||
| Any irAE | 32 (21.3) | 23 (15.3) | 9 (6.0) | 111 | 23 | 13 | 22 |
| Endocrine | 11 (7.3) | 8 (5.3) | 3 (2.0) | 133 | 4 | 4 | 6 |
| Dermatologic | 9 (6.0) | 9 (6.0) | 0 (0) | 168 | 6 | 3 | 5 |
| Gastrointestinal | 4 (2.7) | 3 (2.0) | 1 (0.7) | 124 | 3 | 0 | 4 |
| Hepatic | 3 (2.0) | 2 (1.3) | 1 (0.7) | 96 | 3 | 1 | 2 |
| Hematological | 3 (2.0) | 2 (1.3) | 1 (0.7) | 125 | 2 | 1 | 2 |
| Pulmonary | 2 (1.3) | 1 (0.7) | 1 (0.7) | 154.5 | 2 | 2 | 2 |
| Musculoskeletal | 2 (1.3) | 2 (1.3) | 0 (0) | 96.5 | 2 | 1 | 1 |
| Cardiovascular* | 1 (0.7) | 0 (0) | 1 (0.7) | 8 | 1 | 1 | 1 |
| Nervous system | 1 (0.7) | 0 (0) | 1 (0.7) | 7 | 1 | 1 | 1 |
| Renal | 1 (0.7) | 1 (0.7) | 0 (0) | 103 | 1 | 0 | 1 |
*This case was reported by Isasaki et al.22
Abbreviations: irAE, immune-related adverse event.